Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...